Skip to content
drillr.ai
Sign up

02268.HK

WuXi XDC Cayman Inc

HKSE · Healthcare · Medical - Diagnostics & Research · CN

HKD 67.90
−1.95%
Ask drillr

  • Sep 21, 2026, 10:55 UTC

    WuXi XDC's Singapore production base, the company's first overseas manufacturing site, received GMP release for its BCM3 antibody intermediate and conjugated drug substance dual-function line and DP4 formulation workshop in August 2026.

    Source:

  • Sep 21, 2026, 02:12 UTC

    Hong Kong-listed biopharmaceutical stocks rallied broadly on September 21, with Shanghai Henlius Biotech up over 10%, Junshi Biosciences and Akeso up over 8%, Keymed Biosciences and InnoCare Pharma up over 7%, and RemeGen, GenScript Biotech, WuXi Biologics and Kelun-Biotech up over 6%.

    Source:

  • Sep 17, 2026, 08:45 UTC

    WuXi XDC out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics for development of an ADC candidate against a single target, with upfront, milestone and royalty payments.

    Source:

  • Aug 27, 2026, 10:13 UTC

    WuXi AppTec sold 53.524 million shares of WuXi XDC via block trades for about HK$3.92 billion, expecting an impact of about 3.143 billion yuan on 2026 pre-tax profit.

    Source:

  • Aug 26, 2026, 02:13 UTC

    WuXi XDC signed a new licensing collaboration with a European biotech company in August 2026.

    Source:

  • Aug 25, 2026, 03:33 UTC

    WuXi XDC's stock price surged over 13% to a near one-year high of HK$79 in morning trading on August 25, 2026.

    Source:

  • Aug 24, 2026, 15:16 UTC

    WuXi XDC (02268.HK) announced its interim results for the six months ended June 30, 2026, with revenue of RMB 3.701 billion, up 37% year-on-year, and net profit of RMB 819 million, up 9.9%, with no dividend declared.

    Source: